Publication | Closed Access
Thiazolino 2-Pyridone Amide Inhibitors of <i>Chlamydia trachomatis</i> Infectivity
53
Citations
33
References
2016
Year
Bioorganic ChemistryMicrobial PathogensAntiparasitic AgentPharmacotherapyAntimicrobial ChemotherapyBacterial PathogensPharmaceutical ChemistryDrug ResistanceCompound 1Antimicrobial ResistanceHealth SciencesAntimicrobial Drug DiscoveryAntibacterial AgentAntimicrobial CompoundC. TrachomatisAmide InhibitorsPharmacologyClinical MicrobiologyLead Compound 21ABiomolecular EngineeringAntibioticsMicrobiologyMedicineSmall MoleculesDrug Discovery
The bacterial pathogen Chlamydia trachomatis is a global health burden currently treated with broad-spectrum antibiotics which disrupt commensal bacteria. We recently identified a compound through phenotypic screening that blocked infectivity of this intracellular pathogen without host cell toxicity (compound 1, KSK 120). Herein, we present the optimization of 1 to a class of thiazolino 2-pyridone amides that are highly efficacious (EC50 ≤ 100 nM) in attenuating infectivity across multiple serovars of C. trachomatis without host cell toxicity. The lead compound 21a exhibits reduced lipophilicity versus 1 and did not affect the growth or viability of representative commensal flora at 50 μM. In microscopy studies, a highly active fluorescent analogue 37 localized inside the parasitiphorous inclusion, indicative of a specific targeting of bacterial components. In summary, we present a class of small molecules to enable the development of specific treatments for C. trachomatis.
| Year | Citations | |
|---|---|---|
Page 1
Page 1